These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 17408402)

  • 1. Vaccination with autologous non-irradiated dendritic cells in patients with bcr/abl+ chronic myeloid leukaemia.
    Westermann J; Kopp J; van Lessen A; Hecker AC; Baskaynak G; le Coutre P; Döhner K; Döhner H; Dörken B; Pezzutto A
    Br J Haematol; 2007 May; 137(4):297-306. PubMed ID: 17408402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Testing the safety of clinical-grade mature autologous myeloid DC in a phase I clinical immunotherapy trial of CML.
    Litzow MR; Dietz AB; Bulur PA; Butler GW; Gastineau DA; Hoering A; Fink SR; Letendre L; Padley DJ; Paternoster SF; Tefferi A; Vuk-Pavlović S
    Cytotherapy; 2006; 8(3):290-8. PubMed ID: 16793737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches.
    Volpe G; Cignetti A; Panuzzo C; Kuka M; Vitaggio K; Brancaccio M; Perrone G; Rinaldi M; Prato G; Fava M; Geuna M; Pautasso M; Casnici C; Signori E; Tonon G; Tarone G; Marelli O; Fazio VM; Saglio G
    Cancer Res; 2007 Jun; 67(11):5300-7. PubMed ID: 17545610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T cell recognition of bcr/abl in healthy donors and in patients with chronic myeloid leukaemia.
    Westermann J; Schlimper C; Richter G; Mohm J; Dörken B; Pezzutto A
    Br J Haematol; 2004 Apr; 125(2):213-6. PubMed ID: 15059144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic myeloid leukemia cells express tumor-associated antigens eliciting specific CD8+ T-cell responses and are lacking costimulatory molecules.
    Schmitt M; Li L; Giannopoulos K; Chen J; Brunner C; Barth T; Schmitt A; Wiesneth M; Döhner K; Döhner H; Greiner J
    Exp Hematol; 2006 Dec; 34(12):1709-19. PubMed ID: 17157168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum-free culture of dendritic cells from patients with chronic myeloid leukemia in vitro and estimation of their cytotoxicity.
    Zhao W; Xing P; Wei X; Wang T; Yang D; Li M
    Chin Med J (Engl); 2002 Sep; 115(9):1296-300. PubMed ID: 12411098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imatinib mesylate minimally affects bcr-abl+ and normal monocyte-derived dendritic cells but strongly inhibits T cell expansion despite reciprocal dendritic cell-T cell activation.
    Boissel N; Rousselot P; Raffoux E; Cayuela JM; Soulier J; Mooney N; Charron D; Dombret H; Toubert A; Rea D
    J Leukoc Biol; 2006 Apr; 79(4):747-56. PubMed ID: 16461746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of BCR/ABL gene expression on the proliferative rate of different subpopulations of haematopoietic cells in chronic myeloid leukaemia.
    Primo D; Flores J; Quijano S; Sanchez ML; Sarasquete ME; del Pino-Montes J; Gaarder PI; Gonzalez M; Orfao A
    Br J Haematol; 2006 Oct; 135(1):43-51. PubMed ID: 16939497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells.
    Brauer KM; Werth D; von Schwarzenberg K; Bringmann A; Kanz L; Grünebach F; Brossart P
    Cancer Res; 2007 Jun; 67(11):5489-97. PubMed ID: 17545631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BCR-ABL is not an immunodominant antigen in chronic myelogenous leukemia.
    Grünebach F; Mirakaj V; Mirakaj V; Müller MR; Brümmendorf T; Brossart P
    Cancer Res; 2006 Jun; 66(11):5892-900. PubMed ID: 16740729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating myeloid dendritic cell directly isolated from patients with chronic myelogenous leukemia are functional and carry the bcr-abl translocation.
    Orsini E; Calabrese E; Maggio R; Pasquale A; Nanni M; Trasarti S; Tafuri A; Guarini A; Foa R
    Leuk Res; 2006 Jul; 30(7):785-94. PubMed ID: 16527350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular remission of CML after autotransplantation followed by adoptive transfer of costimulated autologous T cells.
    Rapoport AP; Levine BL; Badros A; Meisenberg B; Ruehle K; Nandi A; Rollins S; Natt S; Ratterree B; Westphal S; Mann D; June CH
    Bone Marrow Transplant; 2004 Jan; 33(1):53-60. PubMed ID: 14578928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects of ST1571 on the development of dendritic cells derived from bone marrow mononuclear cells in patients with chronic myeloid leukemia].
    Zheng SE; Jin J; Tong XM; Qian WB; Xue YQ
    Zhonghua Zhong Liu Za Zhi; 2006 Dec; 28(12):920-3. PubMed ID: 17533744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leukemia-derived dendritic cells can be generated from blood or bone marrow cells from patients with acute myeloid leukaemia: a methodological approach under serum-free culture conditions.
    Kufner S; Zitzelsberger H; Kroell T; Pelka-Fleischer R; Salem A; de Valle F; Schweiger C; Nuessler V; Schmid C; Kolb HJ; Schmetzer HM
    Scand J Immunol; 2005 Jul; 62(1):86-98. PubMed ID: 16091128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts.
    Li L; Giannopoulos K; Reinhardt P; Tabarkiewicz J; Schmitt A; Greiner J; Rolinski J; Hus I; Dmoszynska A; Wiesneth M; Schmitt M
    Int J Oncol; 2006 Apr; 28(4):855-61. PubMed ID: 16525634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia.
    Li Z; Qiao Y; Liu B; Laska EJ; Chakravarthi P; Kulko JM; Bona RD; Fang M; Hegde U; Moyo V; Tannenbaum SH; Ménoret A; Gaffney J; Glynn L; Runowicz CD; Srivastava PK
    Clin Cancer Res; 2005 Jun; 11(12):4460-8. PubMed ID: 15958631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of dendritic cells expressing bcr-abl from CD34-positive chronic myeloid leukemia precursor cells.
    Smit WM; Rijnbeek M; van Bergen CA; de Paus RA; Vervenne HA; van de Keur M; Willemze R; Falkenburg JH
    Hum Immunol; 1997 Apr; 53(2):216-23. PubMed ID: 9129981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Helper and cytotoxic lymphocyte responses to chronic myeloid leukaemia: implications for adoptive immunotherapy with T cells.
    Lewalle P; Hensel N; Guimaraes A; Couriel D; Jiang Y Z; Mavroudis D; Barrett AJ
    Br J Haematol; 1996 Mar; 92(3):587-94. PubMed ID: 8616022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leukaemia-derived dendritic cells can be generated from blood or bone marrow cells from patients with myelodysplasia: a methodological approach under serum-free culture conditions.
    Kufner S; Zitzelsberger H; Kroell T; Pelka-Fleischer R; Salem A; de Valle F; Schmid C; Schweiger C; Kolb HJ; Schmetzer HM
    Scand J Immunol; 2005 Jul; 62(1):75-85. PubMed ID: 16091127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hematological and molecular response evaluation of CML patients on imatinib.
    Gupta A; Prasad K
    J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.